Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?

BACKGROUND: A significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment option for both, CVID and AITP. Nonetheless, due to fewe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Immunol
Päätekijät: Scheuerlein, Philipp, Pietsch, Larissa, Camacho-Ordonez, Nadezhda, Reiser, Veronika, Patel, Smita, Burns, Siobhan O., Warnatz, Klaus, Grimbacher, Bodo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2018
Aiheet:
Immunology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6060403/
https://ncbi.nlm.nih.gov/pubmed/30072997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01656
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia